Futura Medical Regulatory News (FUM)

Futura Medical plc

("Futura" or "the Company")

CSD500 Update

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces an update on the CE mark submission of CSD500, the Company's innovative condom to help healthy men maintain a firmer erection.

The regulatory authority reviewing the CE mark dossier has responded with a number of minor points to be addressed ahead of the award of the CE mark. The points relate to the detailed compilation of the CE mark dossier and do not relate to the substance of the application. We do not believe there is any requirement for further development work or for the generation of any additional data ahead of the CE mark award.

It is the Company's view, and that of its commercial partner, Reckitt Benckiser, that the points can be addressed in a relatively short period of time.

James Barder, Futura's Chief Executive, said: "We will be working closely with our commercial partner to resolve these points as soon as possible and look forward to the award of the CE mark for this innovative new product in due course."

For any further information please contact:

 Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com